dc.contributor.author | Bolbocean, Corneliu | |
dc.contributor.author | van der Pal, Sylvia | |
dc.contributor.author | van Buuren, Stef | |
dc.contributor.author | Anderson, Peter J. | |
dc.contributor.author | Bartmann, Peter | |
dc.contributor.author | Baumann, Nicole | |
dc.contributor.author | Cheong, Jeanie L. Y. | |
dc.contributor.author | Darlow, Brian A. | |
dc.contributor.author | Doyle, Lex W. | |
dc.contributor.author | Evensen, Kari Anne Indredavik | |
dc.contributor.author | Horwood, John | |
dc.contributor.author | Indredavik, Marit Sæbø | |
dc.contributor.author | Johnson, Samantha | |
dc.contributor.author | Marlow, Neil | |
dc.contributor.author | Mendonça, Marina | |
dc.contributor.author | Ni, Yanyan | |
dc.contributor.author | Wolke, Dieter | |
dc.contributor.author | Woodward, Lianne | |
dc.contributor.author | Verrips, Erik | |
dc.contributor.author | Petrou, Stavros | |
dc.date.accessioned | 2023-04-18T06:35:18Z | |
dc.date.available | 2023-04-18T06:35:18Z | |
dc.date.created | 2022-11-03T09:27:16Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | PharmacoEconomics (Auckland). 2022, 41 93-105. | en_US |
dc.identifier.issn | 1170-7690 | |
dc.identifier.uri | https://hdl.handle.net/11250/3063442 | |
dc.description.abstract | Background and Objective
Assessment of health-related quality of life for individuals born very preterm and/or low birthweight (VP/VLBW) offers valuable complementary information alongside biomedical assessments. However, the impact of VP/VLBW status on health-related quality of life in adulthood is inconclusive. The objective of this study was to examine associations between VP/VLBW status and preference-based health-related quality-of-life outcomes in early adulthood.
Methods
Individual participant data were obtained from five prospective cohorts of individuals born VP/VLBW and controls contributing to the ‘Research on European Children and Adults Born Preterm’ Consortium. The combined dataset included over 2100 adult VP/VLBW survivors with an age range of 18–29 years. The main exposure was defined as birth before 32 weeks’ gestation (VP) and/or birth weight below 1500 g (VLBW). Outcome measures included multi-attribute utility scores generated by the Health Utilities Index Mark 3 and the Short Form 6D. Data were analysed using generalised linear mixed models in a one-step approach using fixed-effects and random-effects models.
Results
VP/VLBW status was associated with a significant difference in the Health Utilities Index Mark 3 multi-attribute utility score of − 0.06 (95% confidence interval − 0.08, − 0.04) in comparison to birth at term or at normal birthweight; this was not replicated for the Short Form 6D. Impacted functional domains included vision, ambulation, dexterity and cognition. VP/VLBW status was not associated with poorer emotional or social functioning, or increased pain.
Conclusions
VP/VLBW status is associated with lower overall health-related quality of life in early adulthood, particularly in terms of physical and cognitive functioning. Further studies that estimate the effects of VP/VLBW status on health-related quality-of-life outcomes in mid and late adulthood are needed. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.subject | Helserelatert livskvalitet | en_US |
dc.subject | Health Related Quality of Life | en_US |
dc.title | Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis | en_US |
dc.title.alternative | Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.subject.nsi | VDP::Helsefag: 800 | en_US |
dc.subject.nsi | VDP::Health sciences: 800 | en_US |
dc.source.pagenumber | 93-105 | en_US |
dc.source.volume | 41 | en_US |
dc.source.journal | PharmacoEconomics (Auckland) | en_US |
dc.identifier.doi | 10.1007/s40273-022-01201-2 | |
dc.identifier.cristin | 2068388 | |
dc.relation.project | EU – Horisont Europa (EC/HEU): Grant 733280 | en_US |
dc.relation.project | Norges forskningsråd: 283791 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |